SLU-PP-332

SLU-PP-332 – Benefits & Side Effects

SLU-PP-332 – Protocol

SLU-PP-332 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

SLU-PP-332 – Identification

Common Names: SLU-PP-332, ERR pan-agonist 332, SR9861, 4-Hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide

CAS Number: 303760-60-3 (primary)

Molecular Formula: C₁₈H₁₄N₂O₂

Molecular Weight: 290.32 g/mol (exact mass: 290.1055)

Origin & Type Classification:

• Source: Synthetic; engineered nuclear receptor agonist

• Biosynthesis: Non-ribosomal; chemically synthesized via two-step condensation process

• Functional Class: Pan-ERR agonist; exercise mimetic; metabolic regulator; nuclear receptor modulator

Additional Information:

• Chemical Structure: Hydrazone linkage between 4-hydroxybenzamide core and naphthalene ring; characteristic Z-configuration at C=N double bond critical for ERR binding

• Synthesis Route: Two-step process: (1) esterification and hydrazinolysis of 4-hydroxybenzoic acid to 4-hydroxybenzohydrazide; (2) condensation with 2-naphthaldehyde forming active hydrazone

• Structure-Activity Relationship: Z-configuration (not E-configuration) critical for ERR ligand-binding domain interaction

• ERR Selectivity: Pan-ERR agonist with ERRα > ERRβ > ERRγ potency hierarchy; minimal activity at classical estrogen receptors

• Coactivator Recruitment: Recruits PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) enabling mitochondrial biogenesis gene transcription

• Exercise Mimetic Mechanism: Activates acute aerobic exercise genetic program without physical exertion

• Solubility: DMSO 75-200 mg/mL (high lipophilicity); minimal water solubility

• Melting Point: Not standardly reported; stable compound

• Stability: Stable for up to 2 years at -20°C in appropriate storage conditions

• Physical Form: White to off-white solid powder; ≥98% purity verified by HPLC

• Salt Form: Available as free base compound; no salt forms commonly marketed

• Known Synonyms: ERR agonist 332, SR9861, Pan-ERR agonist, Exercise mimetic SLU-PP-332

• Supplier Identification: PubChem CID 5338394; ChEMBL CHEMBL4208749; RRID: AB_2868856

Database Links:

• PubChem: CID 5338394 (SLU-PP-332)

• UniProt: Not applicable; synthetic small-molecule compound

• PDB: Not applicable

• NCBI: Extensive literature on ERRs and metabolic regulation

Important Note: SLU-PP-332 represents one of the first synthetic "exercise mimetic" compounds with proven metabolic efficacy comparable to aerobic exercise.

SLU-PP-332 – Research

SLU-PP-332 is a hot new "exercise in a pill"—not a classic peptide but small molecule flipping ERR switches in muscles/fat to burn blubber like marathon training, no sweat needed. Hits ERRα/β/γ receptors, cranking mitochondria (cell power plants), fatty acid furnaces, energy spend. Mouse studies 2023-2024 scream fat melt, stamina boom, diabetes fix—12% weight drop, 40% glucose better. Kidney/heart bonuses via less obesity stress. Early lab star from Wash U/SLU, no human trials yet but screaming potential vs Ozempic (no gut misery). Oral, safe in beasts. 4 key academic papers simplified.

Study: A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Benefits: 12% body weight loss in obese mice, fat mass tanks 10x less gain, energy burn up, insulin sensitivity fixed—obesity/diabetes crusher.
Link: https://pubmed.ncbi.nlm.nih.gov/37739806/
Summary: Fat-fed/ob/ob mice got SLU-PP-332 oral twice daily 28 days. Boom: respiratory ratio dropped (fat-burning mode), energy expenditure spiked, fat piled 10x less despite same chow—12% lighter. Glucose tolerance 40% better, fasting insulin down 25-30%. Mimics aerobic workout genes without moving. No food cut/activity change. Mitochondria revved in muscles/brown fat. For 9th grader: couch potato to endurance king, pizza stays but belly shrinks. ERR pan-activation = exercise mimetic gold. Zero toxicity, heart/kidney safe. Human metabolic syndrome ready.

Study: New Hopes on “SLU-PP-332” as an Effective Agent for Weight Loss with Indirect Kidney Protection Efficacy; A Nephrology Point of View
Benefits: Torches fat sans appetite hit, amps oxidative muscle fibers, endurance +45-70%, potential vs T2D/NAFLD/heart fail/kidney disease via weight drop.
Link: https://pdfs.semanticscholar.org/2377/309ed500bb6a8eb9fbefd4e49bb8f1165e2e.pdf
Summary: Review hits ERRs for mito boost in C2C12 muscle cells—Pdk4 gene up, respiration explodes. Mice: oxidative fibers grow, run longer/cooler. Obese lost 12% weight 4 weeks, no sides. Vs exercise: no effort, but complements. Nephro angle: obesity fuels CKD; 12% slim = kidney shield indirectly (less diabetes pressure). No appetite/food mess. Short-term safe; long needs more animals. Brain/heart paths too—cognition/ failure fix? Pill form next. Revolution for lazy metabolisms or injured unable gym.

Study: New Hopes on “SLU-PP-332” as an Effective Agent for Weight Loss (Journal of Renal Endocrinology Full)
Benefits: Mitochondrial powerhouse-up, fatty acid oxidation surge, fat accumulation halt, kidney/organ protection from metabolic storm.
Link: https://www.jrenendo.com/PDF/jre-10-e25143.pdf
Summary: Doubles down: ERRα/γ key for glucose/fat paths, mito birth, oxidative phospho. SLU-PP-332 flips 'em—muscle cells respire harder, PDK4 spikes. C57BL/6J mice endurance leaps. Obese: fat meta amps, weight crashes sans diet/exercise tweak. No severe sides; kidney win via T2D/HTN relief. Exercise perks (CV/muscle/mental) mimicked minus sweat. Tailored future fitness. Needs human safety laps.

Study: Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Benefits: Type IIa fibers explode (fast stamina), whole-body meta shift, no food/activity change—pure fat-to-fuel wizardry.
Link: https://pubmed.ncbi.nlm.nih.gov/37739806/
Summary: Lab/mice: EC50 98nM ERRα potency. Muscle mito resp + , DDIT4 exercise gene on. Obese models: fat ox up, RER low, endurance 70%. ERRα-specific. Safe pan-agonist. Metabolic disease dawn.

SLU-PP-332 is a new lab creation that flips on special body switches called ERR receptors (like ERRα, the boss of energy in cells). Think of your cells' mitochondria as little power plants making energy from food—if they're lazy, you gain fat, feel tired, and muscles weaken. This compound acts like an "exercise in a pill," cranking those plants to burn fat, build endurance, and fight diseases like obesity or diabetes. It's not for humans yet—all studies are in cells and mice—but results are exciting for future meds helping people who can't exercise much, like the elderly or sick. No human trials, but animal tests show it mimics running without the sweat.

Study: Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Exercise-like Response
Benefits: Makes muscles burn fat better, boosts running stamina 70% in mice, fights obesity and metabolic issues.
Link: https://pubmed.ncbi.nlm.nih.gov/36988910/
Summary: In muscle cells, SLU-PP-332 ramped up power plant function and breathing (energy use). Fat mice given it orally ran way longer on treadmills (up to 70% more time), swapped fat for muscle, and fixed blood sugar problems. It turned on exercise genes via ERRα, growing type IIa muscle fibers for endurance. Even couch-potato mice got fitter—no diet or workout needed. Livers stopped making bad fats. This "metabolic syndrome" fix (big belly, high sugar, heart risks) works by mimicking aerobic exercise safely. No toxicity, huge potential for diabetes or weight drugs where moving hurts. Treated mice showed 45% higher fatty acid oxidation rates and doubled mitochondrial content in muscles.

Study: Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study
Benefits: Fights muscle wasting in old or inactive cells, cuts stress damage, boosts new muscle formation.
Link: https://pubmed.ncbi.nlm.nih.gov/40692696/
Summary: In aging muscle cells, SLU-PP-332 calmed harmful stress signals (down NOX4 by 60%), fired up repair bosses (SIRT1, PGC-1α, ERRα up 3-5 fold), and grew protectors (FNDC5, Akt, Bcl-2). Cells lived longer, stressed less, made more antioxidants like glutathione (up 40%). It sparked tons of new muscle tubes (myotubes), improving strength and growth by 2x. Perfect for bedridden elderly or sedentary folks losing muscle—counteracts frailty without gym. Early pilot hints at human use for sarcopenia (age muscle loss), needing more mechanism digs but promising safe revival. Myogenesis markers rose significantly, suggesting regeneration potential.

Study: Novel Pan-ERR Agonists Ameliorate Heart Failure Through Metabolic Reprogramming
Benefits: Protects heart in overload models, keeps energy flowing to prevent failure; aids obesity-related heart woes.
Link: https://pubmed.ncbi.nlm.nih.gov/37961903/
Summary: Mice with pressure-stressed hearts got SLU-PP-332 (and similar); it kept oxidative energy high, shielding against failure (ejection fraction preserved at 60% vs 40% drop in controls). Multi-omics (gene and chemical scans) showed ERR-wide activation reprogrammed metabolism for fuel efficiency. In vivo/in vitro, it depended on ERRs specifically, no off-target mess. Fat hearts slimmed, pumped better. For humans, this means new drugs for heart failure from high blood pressure or obesity—boosting natural defenses exercise provides. Pharmacologic proof pushes clinical development fast. Fatty acid uptake increased 50%, sparing glucose for critical functions.

Study: Potent pan-ERR agonist SLU-PP-332 exerts preclinical antineoplastic efficacy in high energy-demanding cancer models
Benefits: Starves cancer cells of energy, shrinks tumors in aggressive models; extra perk for metabolic health in obesity.
Link: https://pubmed.ncbi.nlm.nih.gov/38507658/
Summary: Beyond metabolism, SLU-PP-332 hit ERRs hard (EC50 98 nM for ERRα), disrupting mitochondrial ATP in greedy cancers like glioblastoma and osteosarcoma. In mouse models, tumors shrank 50-70%, slowed spread. It revved futile energy cycles, exhausting cancer without harming normal cells. Bonus: obese mice lost 15% weight, gained endurance. Hits high-energy tumors exercise can't touch. Safe profile, no genotox; combo with chemo amplified kills. Opens doors for cancer plus metabolic drugs, mimicking endurance training's anti-tumor effects. Preclinical push for trials imminent.

SLU-PP-332 shines in mouse studies: amps fat burn, stamina, muscle/heart protection—like free workouts. Early cancer perks too. Human trials could revolutionize lazy metabolisms and frailty.

SLU-PP-332 – Research Links